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Introduction
The formation of the blood vessel system during embryonic   
development requires a multitude of receptors and adhesion 
molecules that regulate the creation of the first primitive vascular 
plexus (vasculogenesis) and the various remodeling processes 
that lead to the establishment of the mature vascular system. 
Several of the receptors involved in these processes represent 
tyrosine kinases such as the receptors for VEGF and the Tie-2 
receptor. Whereas VEGFR-2 is essential for vasculogenesis and 
sprouting of nascent blood vessels, Tie-2 is important for subse-
quent remodeling processes. Tie-2 is a receptor for the angio-
poietins, of which Ang1 promotes vascular remodeling, maturation, 
and stabilization of the vasculature. Tie-2 knock-out mouse   
embryos die by E10.5 due to endocardial defects, hemorrhaging, 
and impaired vascular network formation (Dumont et al., 1994; 
Sato et al., 1995), similar to the defects of Ang1-null mice that 
die around E12.5, showing comparable deficits in vascular re-
modeling, maturation, and stabilization of blood vessels (Suri et al., 
1996). In contrast, overexpression of the Tie-2 ligand Ang2 mim-
ics the defects caused by Ang1 and Tie-2 ablation (Maisonpierre 
et al., 1997). This argues for an antagonistic function of Ang2 
and illustrates the need to precisely balance the activation level 
of the Tie-2 receptor system during embryonic development.
Tyrosine phosphatases are obvious candidates for signal-
ing molecules that counteract the activation of tyrosine kinase 
receptors. Very few receptor-type protein tyrosine phosphatases 
(RPTPs) are known as regulators of angiogenesis. A mutated form 
of density-enhanced phosphatase (DEP-1, CD148), with the phos-
phatase domain being replaced by the chromophore GFP caused 
embryonic lethality due to vascular malformations (Takahashi   
et al., 2003), and DEP-1 was found to be involved in arterial/ 
venous specification in zebrafish (Rodriguez et al., 2008). Sur-
prisingly, DEP-1 gene ablation in mice does not cause obvious 
defects during embryonic angiogenesis or embryonic lethality 
(Trapasso et al., 2006; Zhu et al., 2008).
In contrast to DEP-1, the vascular endothelial protein   
tyrosine phosphatase (VE-PTP) is an endothelial-specific RPTP 
(Fachinger et al., 1999). Deletion of its cytoplasmic phosphatase 
domain, the transmembrane region, and the most membrane- 
proximal extracellular fibronectin type III-like repeat causes em-
bryonic lethality shortly before 10 d of gestation, accompanied 
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we found that such antibodies mimicked, when added for 22 h to 
cultured allantois explants derived from wild-type mice, the ef-
fect observed in explant cultures of VE-PTP mutant allantoides. 
As shown in Fig. 1 A, endothelial structures visualized by stain-
ing for VE-cadherin were enlarged upon incubation with anti–
VE-PTP antibodies, resulting in a more than 2.5-fold increase in 
average diameter of endothelial cords compared with allantoides 
treated with preimmune antibodies (Fig. 1 B). Determining cord 
diameters is explained in LaRue et al. (2003). The number of 
branching points was reduced by more than twofold (Fig. 1 B). 
Endothelial cell contacts were not affected, as demonstrated by 
staining for the junctional proteins VE-cadherin and endothelial 
cell selective adhesion molecule (ESAM) (Fig. S1). The rat 
monoclonal antibody (mAb) 109.1 against mouse VE-PTP had a 
similar effect, whereas no effect was seen with a control mAb 
against the endothelial antigen ESAM (Fig. S1).
Analyzing whether the antibodies against VE-PTP would 
affect the expression level of VE-PTP, we found that incubation 
of cultured mouse bEnd.5 endothelioma cells with antibodies 
against the extracellular part of VE-PTP for 1 h strongly reduced 
the amount of VE-PTP as tested in immunoblots with antibodies 
against the C terminus (Fig. 1 C). Blocking endocytosis by add-
ing 0.45M sucrose to the culture medium while incubating with 
the antibodies prevented the reduction of VE-PTP protein, indi-
cating that the anti–VE-PTP antibodies down-regulated the levels 
of VE-PTP by triggering endocytosis (Fig. 1 C).
Endocytosis of VE-PTP induced by antibodies could be 
demonstrated by immunofluorescence. As shown in Fig. 2 A, pre-
incubation of endothelioma cells with antibodies against the   
extracellular part of VE-PTP for 20 min followed by fixation, 
permeabilization, and incubation with a labeled secondary anti-
body indeed allowed to detect VE-PTP in granules inside the cells. 
No such staining was observed when cells were not permeabilized 
or when cells were preincubated with preimmune antibodies.   
After 10 min of antibody preincubation, VE-PTP colocalized par-
tially with the early endosomal marker EEA1 (Fig. S2 A). After   
90 min of preincubation time intracellular VE-PTP staining was 
no longer detectable (Fig. S2, B and C). We conclude that anti–
VE-PTP antibodies trigger endocytosis of VE-PTP molecules. 
Endocytosis of VE-PTP was also observed in allantois explant 
cultures (Videos 5–7).
Antibodies against VE-PTP selectively 
down-regulate the Tie-2–associated but not 
the VE-cadherin–associated VE-PTP  
protein fraction
VE-PTP associates with Tie-2 (Fachinger et al., 1999; Saharinen 
et al., 2008) and with VE-cadherin (Nawroth et al., 2002). We 
confirmed this by showing that VE-PTP and Tie-2, endogenously 
expressed in mouse and human endothelial cells, can indeed   
be coprecipitated (Fig. S3). To examine whether it would be   
VE-cadherin or Tie-2 that is involved in the anti–VE-PTP effect 
on the enlargement of vascular structures in allantois tissue,   
we tested whether anti–VE-PTP antibodies affected Tie-2 and   
VE-cadherin–associated VE-PTP molecules in the same way.   
To this end, we preincubated bEnd.5 cells with antibodies against 
the extracellular part of VE-PTP in order to reduce VE-PTP levels. 
by dramatically enlarged blood vessels in the yolk sac, which 
form large cavities (Baumer et al., 2006). Formation of the vas-
cular plexus was generally not affected throughout the embryo, 
yet remodeling was defective. Explants of allantois tissue devel-
oped large endothelial sacs instead of the usual tubular vascular 
network. In addition, heart development was defective (Baumer 
et al., 2006). Defects essentially identical to the VE-PTP trunca-
tion mutants were observed in mice carrying a null allele of the 
VE-PTP gene (Dominguez et al., 2007).
The molecular and cellular mechanisms that cause the   
observed angiogenesis defects in VE-PTP mutant mice are   
unknown. VE-PTP was found to associate with two endothelial 
cell surface membrane proteins essential for angiogenesis. The 
first one was Tie-2, which was found to bind to the cytoplasmic 
phosphatase domain of VE-PTP. Co-expression with VE-PTP   
in transfected cells reduced tyrosine phosphorylation of Tie-2 
(Fachinger et al., 1999; Saharinen et al., 2008). Interestingly, no 
such interactions were found between VE-PTP and VEGFR-2. 
Whether physiological functions of Tie-2 in angiogenesis are 
affected by VE-PTP has not been analyzed previously.
A second association partner of VE-PTP is the endothelial-
specific VE-cadherin (Nawroth et al., 2002). This association is 
mediated via the extracellular domains of both membrane pro-
teins. We have shown that induction of VE-PTP expression in 
cells cotransfected with VE-cadherin enhances the adhesive 
function of VE-cadherin in these cells (Nawroth et al., 2002). 
Recently, we found that silencing of VE-PTP expression in   
endothelial cells indeed strongly reduced the adhesive function 
of VE-cadherin, demonstrating the importance of VE-PTP in reg-
ulating VE-cadherin function in endothelial cells. (Nottebaum   
et al., 2008).
Here we show that antibodies against the extracellular do-
mains of VE-PTP cause vessel enlargement in allantois explants 
resembling the defects in vascular remodeling caused by VE-PTP 
gene disruption. These effects required Tie-2, as they were com-
pletely abolished by lack of Tie-2. We show that mechanistically, 
this  is  due  to  the  anti–VE-PTP  antibodies  triggering  selective   
endocytosis of only the Tie-2–associated, but not the VE-cadherin–
associated VE-PTP protein fraction. VE-PTP dissociation from 
Tie-2 led to activation of Tie-2, thus enhancing endothelial cell 
proliferation and enlargement of vascular structures via activation 
of Erk1/2. Importantly, the antibody effect on vessel enlargement 
could be confirmed in vivo in 1–2-wk-old mice. Our results show 
that VE-PTP is required to control Tie-2 activity and endothelial 
cell proliferation during vascular remodeling in the embryo and 
in newly born mice.
Results
Antibodies against VE-PTP stimulate 
vessel enlargement in allantois explants
We have shown recently that disruption of the VE-PTP gene 
causes defects in vascular remodeling and leads to dramatically 
enlarged endothelial structures in allantois explants (Baumer   
et al., 2006). To elucidate the mechanism underlying this aber-
ration, we tested whether antibodies against the extracellular 
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unchanged (Fig. 2 C). We conclude that anti–VE-PTP antibodies 
selectively displace VE-PTP from Tie-2 and trigger endocytosis   
of these VE-PTP molecules, whereas VE-PTP molecules that are   
associated with VE-cadherin stay unaffected.
In agreement with this interpretation, we found that Tie-2 
was not endocytosed together with VE-PTP upon preincubation 
of living cells with anti–VE-PTP antibodies (Fig. 3 A). In addi-
tion, endocytosis of VE-PTP neither affected the expression of 
VE-cadherin nor that of VE-PTP at endothelial cell contacts 
(Fig. 3 B), and also the staining for the tight junction–associated 
ESAM was unaffected (Fig. S2 C).
Antibodies against VE-PTP activate 
tyrosine phosphorylation of Tie-2
The selective effect of the anti–VE-PTP antibodies on the Tie-2–
associated fraction of VE-PTP molecules prompted us to test 
Subsequently, cells were washed and lysed and residual VE-PTP 
was immunoprecipitated with antibodies against the C terminus of 
VE-PTP. Precipitates were analyzed in immunoblots for VE-PTP 
and for coprecipitated Tie-2 and VE-cadherin. To our surprise, we 
found that the amount of VE-cadherin coprecipitated with anti–
VE-PTP antibodies was unchanged independent of whether cells 
had been pretreated with anti–VE-PTP or with control antibodies 
(Fig. 2 B). Thus, despite the strong down-regulation of VE-PTP, the 
amount of coprecipitated VE-cadherin was not reduced. In con-
trast, the amount of coprecipitated Tie-2 was reduced to a similar 
extent as the amount of VE-PTP that was still available for the   
immunoprecipitation (Fig. 2 B). Analyzing the cell surface expres-
sion of VE-PTP, Tie-2, and VE-cadherin on bEnd.5 cells by FACS   
revealed that cell surface levels of VE-PTP were indeed down- 
regulated by the preincubation with anti–VE-PTP antibodies, 
whereas the cell surface levels of Tie-2 and VE-cadherin were   
Figure 1.  Antibodies against VE-PTP trigger vessel enlargement in allantois explants and down-regulate VE-PTP. (A) Allantois explants from E8.5 wild-type 
embryos were cultured on gelatin-coated ultrathin glass slides in the presence of polyclonal antibodies against VE-PTP (-VE-PTP) or preimmune antibodies 
(control) for 22 h and subsequently stained by indirect immunofluorescence with a monoclonal antibody for VE-cadherin. Bar, 50 µm. (B) Average endo-
thelial cord diameters (top) and branching points (bottom) were determined for 5 control and 5 anti–VE-PTP treated allantois explants, with 30 randomly 
chosen vessels per explant (as shown in A); ***, P < 0,001. (C) Confluent mouse bEnd.5 cells were treated with polyclonal antibodies against VE-PTP or 
preimmune antibodies for 1 h either in normal culture medium or 0.45 M sucrose containing medium (as indicated) to block endocytosis. Aliquots of cell 
lysates with identical protein content were immunoblotted for VE-PTP and equal loading was controlled by blotting for the endothelial antigen ESAM (as 
indicated on the right). Molecular weight markers are indicated on the left.JCB • VOLUME 185 • NUMBER 4 • 2009   660
Figure 2.  Antibodies against VE-PTP trigger endocytosis and down-regulation of Tie-2–associated but not VE-cadherin–associated VE-PTP. (A) Confluent 
bEnd.3 cells were treated with polyclonal antibodies against VE-PTP (-VE-PTP) or preimmune antibodies (control IgG) for 20 min. Subsequently, cells were 
either fixed and permeabilized (top and bottom) or only fixed (middle) and stained with Alexa 568–conjugated secondary antibodies. Cell nuclei were 
counterstained with Hoechst. Bar, 20 µm. (B) bEnd.5 cells were treated with polyclonal antibodies against VE-PTP (-VE-PTP) or preimmune antibodies 
(control) for 1 h. VE-PTP was immunoprecipitated from endothelial cells and analyzed by immunoblotting for coprecipitated VE-cadherin and Tie-2, respec-
tively, or for VE-PTP (as indicated underneath). Aliquots of cell lysates with identical protein content were directly immunoblotted for VE-cadherin or Tie-2 
(bottom). Quantified signal intensities are indicated. Molecular weight markers are indicated. (C) FACS analysis showing the surface expression of Tie-2, 
VE-cadherin, and VE-PTP of bEnd.5 cells after 1 h pretreatment with monoclonal antibodies against VE-PTP (red) or preimmune antibodies (blue). The mean 
fluorescence FACS signal for VE-PTP is indicated in percent (bottom).661 VE-PTP IS AN ESSENTIAL TIE-2 REGULATOR • Winderlich et al.
whether these antibodies stimulate tyrosine phosphorylation of 
Tie-2. Incubating bEnd.5 cells for 1 h with antibodies against 
VE-PTP resulted in a strong increase in tyrosine phosphoryla-
tion of Tie-2 (Fig. 4 A). This effect was rapid, because even anti–
VE-PTP antibody incubations as short as 3 min triggered Tie-2 
phosphorylation (Fig. 4 B). Interestingly, anti–VE-PTP antibodies 
did  not  enhance  tyrosine  phosphorylation  of VE-cadherin,  or   
associated -catenin or plakoglobin (Fig. 5 A), although silencing 
of VE-PTP by siRNA enhanced plakoglobin tyrosine phos-
phorylation (Fig. 5 B and Nottebaum et al., 2008). Again, this 
suggests that the anti–VE-PTP antibodies did not affect the   
VE-cadherin–associated population of VE-PTP molecules.
Figure 3.  Antibodies against VE-PTP do not trigger endocytosis of Tie-2 and leave VE-cadherin and VE-PTP at endothelial cell contacts unaffected.  
(A) Confluent bEnd.3 cells were treated with polyclonal antibodies against VE-PTP (-VE-PTP) or preimmune antibodies (control IgG) for 20 min. Subsequently, 
fixed and permeabilized cells were stained with Alexa 568–conjugated secondary antibodies (internalized VE-PTP, internalized control) and for Tie-2 (Tie-2). 
An anti–Tie-2 staining control is shown in Fig. S5. Cell nuclei were counterstained with Hoechst. Bar, 25 µm. (B) Confluent bEnd.3 cells were treated with 
monoclonal antibodies against VE-PTP (-VE-PTP) or control antibodies (control IgG) for 30 min. Subsequently, fixed and permeabilized cells were stained 
with Alexa 568–conjugated secondary antibodies (internalized VE-PTP, internalized control) and for VE-cadherin and VE-PTP. Cell nuclei were counter-
stained with Hoechst. Internalized VE-PTP was not detected with new antibodies against VE-PTP, probably because epitopes were masked by the antibodies 
that had triggered endocytosis. Bar, 10 µm.JCB • VOLUME 185 • NUMBER 4 • 2009   662
To obtain additional evidence for the role of VE-PTP in 
the regulation of Tie-2 activity, we combined the expression of 
a phosphatase-dead mutant of mouse VE-PTP in HUVEC (using 
adenovirus vectors) with the use of anti–VE-PTP antibodies. 
We expressed either mouse VE-PTP with an intact phosphatase 
domain or in a parallel experiment the phosphatase-dead mutant 
of mouse VE-PTP in HUVEC (using adenovirus) and tested the 
In agreement with the anti–VE-PTP antibody effects on Tie-2 
activation, similar effects were obtained after silencing VE-PTP 
by siRNA in bEnd.5 (Fig. 4 C) and in HUVEC (Fig. 4 D). In addi-
tion, we found that VE-PTP gene disruption leads to tyrosine 
phosphorylation of Tie-2, as was analyzed with endothelioma cells 
generated from gene-disrupted mice (Baumer et al., 2006) ex-
pressing a truncated form of VE-PTP lacking the trans-membrane 
region and the cytoplasmic tail with its phosphatase domain   
(Fig. 4 E). Results were analyzed with three independent cell lines 
for each genotype and quantified (Fig. 4 F).
Figure  4.  VE-PTP  expression  inhibited  by  either  antibodies,  siRNA,  or 
gene disruption triggers Tie-2 tyrosine phosphorylation in endothelial cells. 
(A) bEnd.5 cells were treated with polyclonal antibodies against VE-PTP or 
preimmune antibodies for 1 h and subsequently immunoprecipitated for 
Tie-2, followed by immunoblotting with anti-phosphotyrosine antibodies 
(pTyr) and antibodies against Tie-2. Aliquots of cell lysates with identical 
protein content were directly immunoblotted for VE-PTP and Tie-2 (bottom). 
(B) Similar as in A, except that antibodies were only incubated for 3 min 
(C) bEnd.5 cells were either transfected with control siRNA or with siRNA 
directed against VE-PTP. 24 h later, Tie-2 was immunoprecipitated and 
immunocomplexes (top) or cell lysates (bottom) were analyzed by immuno-
blotting with antibodies against phosphotyrosine (pTyr), Tie-2, VE-PTP, and 
plakoglobin (as indicated). (D) HUVECs instead of bEnd.5 cells were ana-
lyzed as in C. (E) Embryonic endothelioma cells established either from 
wild-type (+/+), heterozygous (+/mut), or homozygous (mut/mut) VE-PTP 
mutant embryos were subjected to immunoprecipitations with antibodies 
against Tie-2. Immunocomplexes were analyzed by immunoblotting with 
antibodies against phosphotyrosine or Tie-2 (as indicated). (F) Quantifica-
tion of Tie-2 tyrosine phosphorylation (±SD) in wild-type (+/+; n = 2 cell 
lines), heterozygous (+/mut; n = 3 cell lines), or homozygous (mut/mut; n = 3 
cell lines) VE-PTP mutant endothelioma, analyzed as in E. **, P < 0,01.
Figure 5.  Down-regulation of VE-PTP by siRNA, but not by anti–VE-PTP   
antibodies, enhances tyrosine phosphorylation of VE-cadherin–associated 
plakoglobin. (A) bEnd.5 cells were treated with polyclonal antibodies against 
VE-PTP (-VE-PTP) or preimmune antibodies (control) for 1 h and subsequently 
immunoprecipitated for VE-cadherin, followed by immunoblotting with anti-
bodies against phosphotyrosine (pTyr), VE-cadherin, or plakoglobin. Aliquots 
of cell lysates with identical protein content were directly immunoblotted for 
VE-PTP and VE-cadherin (bottom). (B) Similar as in A, except that antibody 
preincubation of cells was replaced by transfection with either control siRNA 
or VE-PTP siRNA.663 VE-PTP IS AN ESSENTIAL TIE-2 REGULATOR • Winderlich et al.
Vessel enlargement induced by anti–VE-PTP 
antibodies requires Tie-2
Despite the essential function of Tie-2 during embryonic vascular 
remodeling, we have found that allantois explants from Tie-2–null 
mice develop normal vascular networks (Baumer et al., 2006). 
However, the selective anti–VE-PTP antibody effect on Tie-2 acti-
vation suggested that VE-PTP deficiency, caused by either gene 
disruption or by antibody-mediated down-regulation of VE-PTP, 
effect of antibodies against the extracellular part of mouse   
VE-PTP on Tie-2 activation in these cells. Importantly, the anti-
bodies we used did not crossreact with human VE-PTP. As we 
expected,  the  expression  of  intact VE-PTP  reduced  tyrosine 
phosphorylation of Tie-2, whereas the dominant-negative mu-
tant enhanced Tie-2 activity (Fig. 6, A and B). Incubation of the 
cells with antibodies against mouse VE-PTP induced activation 
of Tie-2 in cells that expressed intact mouse VE-PTP (Fig. 6 A). 
Intriguingly, the same antibodies had the opposite effect in   
HUVEC expressing the dominant-negative form of VE-PTP 
(Fig. 6 B). This clearly rules out indirect effects of the antibodies 
on Tie-2 activation and shows that it is the dissociation of the   
intact phosphatase VE-PTP from Tie-2 that leads to the activation 
of Tie-2, whereas the dissociation of the dominant-negative form 
of VE-PTP makes it accessible again for intact human VE-PTP, 
which then leads to the dephosphorylation of Tie-2.
VE-PTP counterbalances activation of Tie-2 
by Ang1
To determine whether VE-PTP indeed counterbalances the acti-
vation of Tie-2 by Ang1, we combined silencing of VE-PTP by 
siRNA in bEnd.5 cells with the stimulation with Ang1. As 
shown in Fig. 7 A, a combined treatment with Ang1 and VE-PTP 
siRNA stimulated Tie-2 phosphorylation to a greater extent than 
a combined treatment with Ang1 and control siRNA. This sug-
gests that VE-PTP indeed counteracts the activation of Tie-2 by 
Ang1. Ang2 enhanced the phosphorylation of Tie-2 in endo-
thelial cells only weakly and had no significant additive effect in 
combination with silencing of VE-PTP expression (Fig. 7 A). 
However, it cannot be ruled out that VE-PTP may also counter-
act small activation effects of Ang2.
Tyrosine phosphorylation analyzed in such experiments in-
deed represented proper Tie-2 activation because these results 
could be verified in HUVEC for tyrosine residue 992 in the acti-
vation loop of the human Tie-2 kinase domain, the first tyrosine 
phosphorylated upon activation (Shewchuk et al., 2000; Murray 
et al., 2001) (Fig. 7 B). Likewise, down-regulation of VE-PTP 
with antibodies also further enhanced Ang1 stimulated phosphory-
lation of tyrosine 992 of Tie-2 in mouse bEnd.5 cells (Fig. 7 C). 
We conclude that antibodies against VE-PTP enhance the activa-
tion of the kinase domain of Tie-2 by Ang1.
We tested whether VE-PTP is constitutively associated 
with Tie-2 or whether this would be enhanced upon activation 
of Tie-2. Interestingly, we found that COMP-Ang1 stimula-
tion of Tie-2 in bEnd.3 cells clearly increased the association 
of VE-PTP with Tie-2 (Fig. 7 D). A similar effect was also 
seen with 600 ng/ml Ang1, but not with the same concentra-
tion of Ang2 (not depicted). This suggests that Ang1 stimu-
lates activation of Tie-2 and simultaneously triggers a negative 
feed back process that limits activation by enhancing the asso-
ciation of Tie-2 with VE-PTP, and thus eventually balances 
Tie-2 receptor activity.
Interestingly, antibody-stimulated endocytosis of VE-PTP 
also triggered tyrosine phosphorylation of Tie-1 and this effect re-
quired the expression of Tie-2, as it was not observed in Tie-2–null 
endothelioma cells (Fig. 7 E). This shows that VE-PTP specifi-
cally regulates Tie-2, whereas Tie-1 is indirectly affected.
Figure 6.  VE-PTP regulates Tie-2 phosphorylation via its active phospha-
tase. (A) HUVECs either untransfected, or expressing GFP or expressing 
mouse Flag-VE-PTP (as indicated above) were either untreated or treated 
with polyclonal antibodies against mouse VE-PTP or preimmune antibodies 
(as indicated above) for 1 h and subsequently immunoprecipitated for Tie-2, 
followed by immunoblotting with anti-phosphotyrosine antibodies (pTyr) 
and antibodies against Tie-2. Aliquots of cell lysates with identical protein 
content were directly immunoblotted for Flag-VE-PTP and hVE-PTP (bottom). 
Quantified signal intensities are indicated. (B) As in A with mouse Flag-
VE-PTP being replaced by the corresponding inactive phosphatase mutant 
Flag-VE-PTP-C/S. White lines indicate that intervening lanes have been 
spliced out.JCB • VOLUME 185 • NUMBER 4 • 2009   664
explants had a similar effect as the anti–VE-PTP antibodies 
(Fig. 8 B), further supporting the assumption that VE-PTP controls 
vascular remodeling by counteracting the activation of Tie-2.
Anti–VE-PTP antibodies trigger vessel 
enlargement by enhancing endothelial  
cell proliferation via stimulating Tie-2  
and Erk1/2
To determine how Tie-2 hyper-activation upon down-regulation of 
VE-PTP leads to the enlargement of endothelial structures in   
allantois explants, we directly visualized the formation of endo-
thelial structures in the explants. To this end, we performed live 
imaging of allantois explants from mice expressing a VE-cadherin-
GFP fusion protein via a cDNA construct knocked into the VE-
cadherin locus, thereby replacing the endogenous VE-cadherin 
allele. Mice homozygous for the VE-cadherin-GFP allele devel-
oped normally and were viable (unpublished data). Allantois 
explants from these mice were cultured for 12 h and then incu-
bated for another 12 h in the presence of either anti–VE-PTP 
antibodies, or preimmune antibodies or Ang1. As shown in the 
respective Videos (Videos 1–3), Ang1 and anti–VE-PTP anti-
bodies, but not control antibodies, rapidly increased the area cov-
ered with endothelial structures and stimulated endothelial cell 
division. Dividing endothelial cells could clearly be identified as 
cells transiently rounding up. Staining of explants with phospho-
Histone 3 antibodies subsequent to live imaging revealed that round 
cells still visible at the end of the observation period were indeed 
positive for the mitosis marker (Fig. 9, A and B). The stimulatory 
effect of anti–VE-PTP antibodies on endothelial proliferation was 
quantified by costaining allantois explants for PECAM-1 and   
phospho-Histone 3 and analyzing them by laser scanning confocal 
microscopy with the help of 3D software (Video 4), which allowed 
to unambiguously determine the endothelial nature of phospho-
Histone 3 positive nuclei. Quantification revealed that anti–VE-PTP 
antibodies increased the number of mitotically active endothelial 
cells by 2.8-fold in comparison to allantoides cultured in the pres-
ence of control antibodies (Fig. 9 C). In agreement with this, the 
number of endothelial cells in a defined volume had increased by a 
factor of 4.4, although the number of sprouts was not increased. 
Thus, anti–VE-PTP antibodies stimulate endothelial cell prolifera-
tion within cord structures.
Activation of Tie-2 feeds into various signaling pathways. 
Among those only Tie-2–dependent activation of Erk1/2 has been 
reported to trigger proliferation of cultured endothelial cells (Kanda 
et al., 2005). This prompted us to test whether anti–VE-PTP anti-
bodies stimulate Erk1/2 in mouse endothelioma cells. Indeed, 
we found a rapid (10 min) and transient activation of Erk1/2   
(Fig. 9 D). This activation was dependent on Tie-2 because it was 
only seen in endothelioma cells established from Tie-2–expressing 
mice, but not in endothelioma cells established from Tie-2
/ 
mice (Fig. 9 E). Similar results were found with three indepen-
dently derived cell lines from wild-type and from Tie-2
/ 
mice, respectively.
Activation of Erk1/2 with anti–mouse VE-PTP antibodies 
was also seen in HUVEC that were transduced with mouse Flag-
VE-PTP (Fig. 9 G). In addition, we found that the kinase Akt 
was phosphorylated at serine 473 (Fig. 9 G). Activation of Akt is 
might affect vascular remodeling in the allantois through hyper-
activation of Tie-2. If this were the case, anti–VE-PTP anti-
bodies should not affect vascular remodelling in Tie-2–null 
allantoides. Indeed, we found that antibodies against VE-PTP 
enlarged cord structures only in Tie-2
+/+ and Tie-2
+/, but not in 
Tie-2
/ allantoides (Fig. 8 A). In agreement with this, the acti-
vating Tie-2 ligand Ang1 when added to wild-type allantois   
Figure 7.  VE-PTP counterbalances Ang1 activation of Tie-2 and regulates 
Tie-1 tyrosine phosphorylation dependent on Tie-2. (A) bEnd.5 cells were 
either transfected with control siRNAs or with siRNAs directed against VE-PTP. 
24 h later, cells were stimulated either with 600 ng/ml Ang1 or 600 ng/ml 
Ang2 for 10 min, or unstimulated (unstim). Immunoprecipitates of Tie-2 (top 
two panels) or cell lysates (bottom two panels) were immunoblotted for the   
indicated antigens. (B) HUVECs were either transfected with control siRNAs 
or with siRNAs directed against hVE-PTP. 24 h later, siRNA-transfected cells 
(left two lanes) and untransfected cells, stimulated either with 600 ng/ml 
Ang1 for 10 min or unstimulated (right two lanes), were subjected to immuno-
precipitations for Tie-2, followed by immunoblotting with antibodies against 
the phosphorylated tyrosine 992 in the active loop of the kinase (pTyr 992)   
and Tie-2. Aliquots of cell lysates were immunoblotted directly for hVE-PTP 
and Tie-2 (bottom two panels). White line indicates that intervening lanes 
have been spliced out. (C) bEnd.5 cells were treated either with polyclonal 
antibodies against VE-PTP (-VE-PTP) or preimmune antibodies (control) for 
1 h, followed by either Ang1 stimulation for 10 min (Ang1) or no stimula-
tion (unstim). Phosphorylation of tyrosine 992 was analyzed as described 
for B. Quantified signal intensities are indicated. (D) bEnd.5 cells were 
stimulated with 200 ng/ml COMP-Ang1 for 10 min or left untreated. VE-PTP 
immunoprecipitates (top three panels) and cell lysates (bottom two panels) 
were analyzed by immunoblotting for Tie-2, VE-cadherin, and VE-PTP as indi-
cated on the right. (E) Embryonic endothelioma cells established either from 
wild-type (+/+) or Tie-2–deficient (/) embryos were antibody pretreated 
as indicated and subjected to immunoprecipitations with antibodies against 
Tie-1. Immunocomplexes were analyzed by immunoblotting with antibodies 
against phosphotyrosine or Tie-1 (as indicated). Aliquots of cell lysates were 
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mice daily for 5 d with 100 µg of anti–VE-PTP antibodies. 
Blood vessels were visualized in vibratome sections of the 
tongue by staining for PECAM-1. As shown in Fig. 10 A, ves-
sels in the dermal papillae and draining venules were clearly en-
larged.  Quantification  revealed  that  polyclonal  antibodies 
against VE-PTP enlarged vessels by 82%, compared with tissue 
sections from mice treated with control antibody and the mAb 
109.1  against VE-PTP,  which  increased  vessel  diameters  by 
57% (Fig. 10 B). These effects are reminiscent of what was re-
ported for the influence of Ang1 on vessel enlargement in new-
born mice (Thurston et al., 2005). Indeed, we could show that 
tyrosine phosphorylation of Tie-2 was enhanced in the animals 
upon anti–VE-PTP antibody injection, as analyzed in immuno-
blots of lung tissue of these animals (Fig. 10 C). This effect was 
accompanied with a fivefold increase of the number of phospho-
Histone 3 positive endothelial nuclei (Fig. 10, E and F), suggest-
ing that vessel enlargement was caused by hyperplasia. Similar 
as  for  tongue  tissue,  anti–VE-PTP  antibodies  also  enlarged 
blood vessels of the trachea (Fig. 10 D). Collectively, our results 
suggest that VE-PTP is required to balance the activity of Tie-2 
during vascular remodeling in young mice. In addition, our re-
sults demonstrate that the described anti–VE-PTP antibody ef-
fects on vascular remodeling and Tie-2 activity are not limited to 
explant cultures devoid of blood flow.
Discussion
VE-PTP, the first known endothelial-specific receptor-type tyro-
sine phosphatase, associates with Tie-2 and VE-cadherin and   
a step in another signaling pathway known to be stimulated by 
Tie-2 (Brindle et al., 2006).
To test whether activation of Erk triggered by anti–VE-PTP 
antibodies would be involved in the anti–VE-PTP induced en-
largement of endothelial structures in allantois explants, we co-
incubated explants with the antibodies together with 50 µM of 
the Erk inhibitor PD98059, a concentration that blocked the 
anti–VE-PTP effect on Tie-2 activation in bend.5 cells (Fig. 9 F). 
As shown in Fig. 9 H, the inhibitor could strongly reduce the 
antibody effect on enlargement of the vascular structures. Quan-
tification of the effect revealed a 67% inhibitory effect of the 
Erk1/2 inhibitor (Fig. 9 I). Another inhibitor of Erk1/2, U0126, 
also inhibited the anti–VE-PTP effect on vessel enlargement in 
allantois explants (Fig. S4). In addition, this inhibitor reversed 
the stimulatory effect of the anti–VE-PTP antibodies on prolif-
eration, as analyzed by counting phospho-Histone 3 positive 
endothelial nuclei (control antibodies 6.25 ± 0.35; anti–VE-PTP 
antibodies 14.8 ± 4.5; anti–VE-PTP antibodies plus PD98059 
5.5 ± 1.24 mitotic endothelial nuclei per volume allantois;   
P < 0.001). In combination with the report by Kanda et al. (2005), 
these results strongly suggest that the down-regulation of VE-
PTP by antibodies leads to the activation of Tie-2, which in turn 
stimulates endothelial proliferation via stimulating the MAP ki-
nase Erk1/2.
Antibodies against VE-PTP induce blood 
vessel enlargement in 1–2-wk-old mice
To test whether antibodies against VE-PTP can indeed affect 
vascular remodeling in the living animal, we injected 7-d-old 
Figure 8.  Vessel enlargement induced by anti–VE-PTP antibodies requires Tie-2. (A) Allantois explants from E8.5 Tie-2 +/+, Tie-2 +/, or Tie-2 / 
embryos (as indicated) were cultured on gelatin-coated ultrathin glass slides in the presence of polyclonal antibodies against VE-PTP for 22 h. (B) Allantois 
explants from E8.5 embryos were cultured in medium (untreated) or in the presence of 600 ng/ml Ang1. Subsequently, endothelium was visualized in all 
samples in A and B by indirect immunofluorescence staining for VE-cadherin. Bars, 50 µm.JCB • VOLUME 185 • NUMBER 4 • 2009   666
In addition, we found that the anti–VE-PTP antibodies elicit 
enlargement of vascular structures in allantois explants and in 
1–2-wk-old mice, accompanied by enhanced endothelial cell 
proliferation. Most importantly, enlargement of vascular struc-
tures by these antibodies was eliminated in the absence of   
Tie-2 and required activation of Erk1/2. Our results establish 
VE-PTP as an essential negative regulator of Tie-2 during blood 
vessel remodeling, providing a mechanism for how VE-PTP 
affects angiogenesis.
is essential for vascular remodeling during embryonic develop-
ment. In this study we show that VE-PTP controls vascular re-
modeling via regulating the ability of Tie-2 to drive endothelial 
cell proliferation. These mechanistic insights into the physio-
logical function of VE-PTP were enabled by antibodies against 
VE-PTP, which selectively dissociate VE-PTP from Tie-2 but 
not from VE-cadherin. The antibodies stimulated Tie-2 activa-
tion, as documented by increased tyrosine phosphorylation of 
Tie-2 and activation of the downstream signaling target Erk1/2. 
Figure 9.  Anti–VE-PTP antibody treatment of 
allantois  explants  stimulates  endothelial  cell 
proliferation  and  enlargement  of  endothelial 
cords through activation of Erk1/2. (A) Allan-
tois explants of E8.5 embryos from knock-in 
mice expressing VE-cadherin-GFP from the VE-
cadherin genetic locus were cultured on gela-
tin-coated ultrathin glass slides for 12 h and 
were then analyzed by live imaging during the 
next 12 h (see Video 2), while they were cul-
tured in the presence of polyclonal antibodies 
against VE-PTP. Subsequently, allantoides were 
fixed  and  double  stained  for  PECAM-1  and 
phospho-Histone 3. Arrows indicate proliferat-
ing endothelial cells with a characteristic round   
cell shape. Bar, 20 µm. (B) Same as in A, depict-
ing larger areas of the explants. Bar, 100 µm. 
(C) Percentage of phospho-Histone 3–positive 
endothelial cells per volume tissue in E8.5   
allantois explants cultured with polyclonal anti-
bodies against VE-PTP or preimmune antibodies 
for 12 h. *, P < 0,05. (D) bEnd.5 cells were 
treated with mAb against ESAM (control) or 
for indicated time periods with a mAb against 
VE-PTP. Cell lysates were analyzed by immuno-
blotting  with  anti–phospho-Erk1/2–specific 
antibodies  (pT202/pY204)  and  antibodies 
against Erk1/2. Treatment with mAb against 
ESAM gave a similar result as in the absence 
of antibodies (not depicted). (E) Endothelioma 
cells of wild-type genotype (Tie-2 +/+) or de-
ficient for Tie-2 (Tie-2 /) were treated with 
monoclonal antibodies against ESAM (control)   
or against VE-PTP for 1 h, followed by immuno-
blotting  cell  lysates  with  anti–phospho-
Erk1/2–specific  antibodies  (pT202/pY204) 
and antibodies against Erk1/2, as indicated 
on the right. (F) bEnd.5 cells were treated with 
50 µM of the Erk1/2 inhibitor PD98059 (PD 
98059) or DMSO only (control) for 30 min, 
followed  by  incubation  with  a  control  mAb 
(control)  or  mAb  against  VE-PTP  (-VE-PTP) 
in the presence of the inhibitor or DMSO for   
20 min. Cell lysates were analyzed by immuno-
blotting  with  anti–phospho-Erk1/2–specific 
antibodies  (pT202/pY204)  and  antibodies 
against  Erk1/2.  (G)  Mouse  Flag-VE-PTP  ex-
pressing HUVECs were treated with polyclonal 
antibodies against VE-PTP or preimmune anti-
bodies for 20 min and subsequently cell lysates 
were analyzed by immunoblotting with anti–
phospho-Erk1/2–specific antibodies (pT202/
pY204), anti–phospho-Akt–specific antibodies 
(Ser473) and antibodies against Erk1/2 and 
Akt. (H) Allantois explants from E8.5 wild-type 
embryos were cultured on gelatin-coated glass 
slides either in the presence of Erk1/2 inhibitor 
PD 98059 (PD 98059), polyclonal antibodies against VE-PTP (-VE-PTP), or the combination of both (-VE-PTP + PD 98059) or left untreated for 22 h. Endo-
thelial structures were stained with a mAb against VE-cadherin by indirect immunofluorescence Bar, 100 µm. (I) Quantification of the experiment illustrated 
in H. Average endothelial cord diameters were determined for allantois explants that were left untreated (untreated, n = 3), cultured in the presence of 
Erk1/2 inhibitor PD 98059 (PD 98059, n = 3), polyclonal antibodies against VE-PTP (-VE-PTP, n = 11), or the combination of both (-VE-PTP + PD 98059, 
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Precise balancing of positive and negative stimulation of 
Tie-2 is essential for vessel remodeling and angiogenesis. A lack 
of activation caused by deleting the Tie-2 gene itself or by   
disrupting the gene for the agonist Ang1 leads to embryonic 
vascular malformations and lethality (Dumont et al., 1994; Sato 
et al., 1995; Suri et al., 1996), a similar phenotype that is ob-
served upon overexpression of the antagonistic ligand Ang2 
(Maisonpierre et al., 1997). On the other hand, hyper-activation 
Figure 10.  Antibodies against VE-PTP induce blood vessel enlargement and endothelial proliferation in juvenile mice and lead to activation of Tie-2.  
(A) 7-d-old wild-type mice were injected daily i.p. with 100 µg antibodies against VE-PTP (-VE-PTP) or preimmune antibodies (control) for a period of 7 d. 
100-µm vibratome sections of tongues were immunostained for PECAM-1. Bar, 60 µm. (B) Average vessel diameter in the tongue of wild-type mice injected 
daily i.p. with 100 µg polyclonal (-VE-PTP pAb), or monoclonal (a-VE-PTP mAb) antibodies against VE-PTP, preimmune antibodies (control pAb), or mono-
clonal antibodies against ESAM (control mAb), respectively, for a period of 7 d. In each case three animals were analyzed. (C) 7-d-old wild-type mice were 
treated as described for A. Lungs of mice were lysed and subjected to immunoprecipitation for Tie-2 and subsequent immunoblotting with antibodies either 
against phosphorylated tyrosine or against Tie-2 (as indicated). White line indicates that intervening lanes have been spliced out. (D) Mice were treated 
as in A and trachea whole mounts were immunostained for PECAM-1. Arrowheads indicate enlarged blood vessels. L, lymphatic vessels. Bar, 50 µm.   
(E) Mice were treated for 4 d as in A and vibratome sections of tongues were immunostained for PECAM-1 and phospho-Histone 3. Asterisk, nonendothelial 
nucleus; arrowheads, endothelial nuclei. Bar, 50 µm. (F) Quantification of the experiment illustrated in E with phospho-Histone 3–positive endothelial nuclei 
counted per volume tissue (38 × 200 × 500 µm). ***, P < 0,001.JCB • VOLUME 185 • NUMBER 4 • 2009   668
Like them, we found that Tie-2–dependent proliferation was   
independent from sprout formation and occurred within endothelial 
cord structures.
Kanda et al. (2005) have shown that blocking Erk can par-
tially inhibit Ang1-stimulated endothelial cell proliferation of 
cultured endothelial cells. This is in good agreement with our 
finding that treatment with anti–VE-PTP antibodies feeds into 
the Tie-2–signaling pathway leading to Erk activation. Impor-
tantly, the fact that the Erk1/2 inhibitors PD98059 and U0126 
blocked the anti–VE-PTP effect on endothelial cell proliferation 
and on enlargement of vascular structures in the allantois indi-
cates that Tie-2 triggers endothelial proliferation in the allantois 
via Erk1/2 and that VE-PTP counteracts this pathway. Collec-
tively, these results indicate that anti–VE-PTP antibodies induce 
enlargement of vascular structures in the allantois by stimulat-
ing endothelial cell proliferation via the Tie-2, Erk1/2 pathway.
It is intriguing that VE-PTP molecules associated with Tie-2 
were selectively sensitive to anti–VE-PTP antibody-triggered 
dissociation and endocytosis, whereas VE-cadherin–associated 
VE-PTP molecules were not sensitive for this effect. Likewise, 
anti–VE-PTP antibodies selectively affected tyrosine phosphory-
lation of Tie-2, but not the phosphorylation pattern of the com-
ponents of the VE-cadherin complex in endothelial adherens 
junctions. We assume that VE-PTP complexed with VE-cadherin 
may not be accessible for antibodies, possibly masked within 
VE-cadherin clusters at cell contacts. Indeed, incubation of liv-
ing, intact endothelial cells or allantois explants with anti–VE-PTP 
antibodies did not allow to stain endothelial cell contacts, whereas 
fixing and permeabilizing the specimens rendered extracellular 
epitopes of VE-PTP accessible to antibody staining (Fig. 3 and 
Videos 5–7).
In conclusion, our results establish VE-PTP as an essen-
tial negative regulator of Tie-2, which controls Tie-2–driven   
endothelial cell proliferation, which in turn affects blood vessel 
remodeling during embryonic development and determines blood 
vessel size during perinatal growth. In light of the publications 
analyzing the function of the Tie-receptor system in tumor   
angiogenesis (Shim et al., 2007) it will be interesting to test a 
potential role of VE-PTP in this pathological process. Furthermore, 
because VE-PTP is an endothelial-specific transmembrane pro-
tein and antibodies against its extracellular part affect endothelial 
cell proliferation and angiogenesis in vivo, VE-PTP is generally 
an easily accessible, interesting novel target for pro- or anti- 
angiogenic therapeutic interventions.
Materials and methods
Mice
Tie-2–deficient mice were provided by Daniel Dumont (Sunnybrook and 
Women’s Research Institute, Toronto, Canada; Dumont et al., 1994). For 
timed matings, mice were mated for 3 h.
Reagents and antibodies
The following reagents and antibodies were used: gelatin (Sigma-Aldrich), 
mowiol (Sigma-Aldrich), fibronectin (Sigma-Aldrich), Hoechst (Invitrogen), 
PD 98059 (Calbiochem), COMP-angiopoietin-1 (201–314; Qbiogene), 
angiopoietin-1  (923-AN;  R&D  Systems),  angiopoietin-2  (623-AN;  R&D 
Systems), mAb 109.1 against VE-PTP (Baumer et al., 2006), pAb VE-PTP-C 
against VE-PTP (crossreactive to the human homologue hVE-PTP; Nawroth 
et al., 2002), pAb PTP 1–8 against the extracellular fibronectin type III-like 
of Tie-2 via a missense mutation in the kinase domain leads to 
venous malformations in human patients (Vikkula et al., 1996), 
and deletion of the gene for the antagonist Ang2 affects re-
modeling in hyaloid vasculature in the eye of newborn mice and 
lymphatic patterning (Gale et al., 2002). Interestingly, defects in 
Ang2-deficient  mice  were  limited  to  postnatal  development, 
and no defects were found during embryonic vascular develop-
ment in these mice. Thus, VE-PTP represents the first negative 
regulator of Tie-2 essential for embryonic angiogenesis. We can 
not, of course, rule out that VE-PTP gene disruption affects ad-
ditional molecular mechanisms besides Tie-2 signaling, e.g., 
VE-cadherin or other still-unknown substrates. However, the 
vascular aberrations caused by our anti–VE-PTP antibodies in 
allantois explant cultures were strictly dependent on Tie-2 and 
therefore identify Tie-2 as an essential substrate for VE-PTP 
during embryonic vascular remodeling.
We assume that VE-PTP represents a negative feedback 
control mechanism that limits the activation of Tie-2. In agree-
ment with this, stimulation of Tie-2 with Ang1 leads to increased 
association of Tie-2 and VE-PTP, enabling the agonist to trigger 
activation and at the same time to launch the negative mecha-
nism that ensures that the signal is switched off again. Whether, 
in addition, a ligand for VE-PTP may exist that could induce 
uptake of VE-PTP and thereby indirectly could enhance Ang1-
driven activation of Tie-2 is unknown, and may be an interesting 
hypothesis to test in the future.
The effects of our anti–VE-PTP antibodies on blood ves-
sel enlargement in young mice are similar to the effects observed 
in mice either injected with Ang1 or COMP-Ang1 (Thurston   
et al., 2005; Kim et al., 2007) or overexpressing COMP-Ang1 via 
adenovirus vectors (Cho et al., 2005). However, as these studies 
were based on exogenously added large doses of Ang1, it could 
not be determined whether physiological levels of Ang1 would 
indeed play a role in the normal regulation of vessel size during 
perinatal development. Because the anti–VE-PTP antibodies sim-
ply dissociate a negative regulator from Tie-2, our results sug-
gest that Tie-2–stimulating ligands are indeed acting in newborns 
to determine vessel size.
It is interesting that antibodies against VE-PTP also stimu-
lated Tie-1 activation and that this only occurred in the presence 
of Tie-2. This is in agreement with other studies demonstrating 
that Tie-1 activation by Ang1 depends on Tie-2 (Saharinen et al., 
2005; Yuan et al., 2007).
Tie-2 activation triggers various signaling pathways and 
biological activities, such as survival and protection from apop-
tosis, migration, permeability, tube formation, and sprouting, as 
has been summarized in excellent reviews (Brindle et al., 2006; 
Eklund and Olsen, 2006). However, studies on the ability of Ang1 
to stimulate proliferation of cultured endothelial cells are contro-
versial, ranging from no effect (Davis et al., 1996; Witzenbichler 
et al., 1998; Fujikawa et al., 1999) to mild effects (Koblizek 
et al., 1998; Teichert-Kuliszewska et al., 2001) to substantial ef-
fects (Kanda et al., 2005). The in vivo studies with Ang1 and 
COMP-Ang1 in newborns (Cho et al., 2005; Thurston et al., 
2005; Kim et al., 2007) suggest that vessel enlargement was ac-
companied by endothelial cell proliferation, establishing that 
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and aliquots were set aside for direct blot analysis; for IP aliquots were in-
cubated for 2 h at 4°C with protein A– or G–Sepharose loaded with the re-
spective antibodies. Immunocomplexes were washed five times with lysis 
buffer and analyzed by SDS-PAGE. Total cell lysates (3 × 10
5 cells/lane) 
or immunoprecipitated material was separated by electrophoresis on 6% 
(IP) or 8% (direct immunoblots of cell lysates) SDS-PAGE and transferred to 
nitrocellulose (Whatman) by wet blotting. Blots were analyzed as described 
previously (Nawroth et al., 2002) or with fluorescent dye-coupled second-
ary antibodies and Starion fluorescence Image Analyzing system (Fujifilm). 
For detection of phosphotyrosine, milk powder in the blocking buffer was 
replaced by 2% BSA and 200 µM Na3VO4 was added.
RNA interference
For RNA interference of mouse and human VE-PTP expression the following 
siRNAs were used: VE-PTP-34: 5-CCUCACUGAGGGUAACAGU-3 (tar-
geting mVE-PTP) and siPTP-82: 5-GACAGUAUGAGGUGGAAGU-3 (tar-
geting hVE-PTP; Ambion). For negative controls an siRNA was used that 
does not target any known mammalian gene (5-UUCUCCGAACGUGU-
CACGU-3; QIAGEN 1022076). Routinely 10
6 bEnd.5 cells or HUVECs 
were transfected with 3 or 4 µg of siRNA, respectively, using nucleofection 
(Amaxa Biosystems) according to the manufacturer’s instructions. For detec-
tion of tyrosine phosphorylation, single nucleofection reactions of bEnd.5 
cells and HUVECs were scaled up fivefold and threefold, respectively.
Allantois explant cultures and immunolabeling
Allantoides were dissected from E8.0 to E8.5 C57BL/6 wild-type or Tie-2–
deficient embryos, cultured for 22 h before fixation, in the presence of   
50 µg/ml mAb 109.1 (anti–VE-TP), 1G8.1 (anti-ESAM), pAb PTP 1–8 (anti–
VE-PTP), pAb VE-19 (anti-ESAM), or preimmune serum, or left untreated for 
12–22 h. For stimulation with growth factors, allantoides were cultured in 
the presence of 600 ng/ml COMP-Ang1 or Ang1. For inhibiting Erk1/2 
activation, allantoides were pretreated with 50 µM/L PD 98059 or 10 µM 
U0126 for 30 min and subsequently incubated with antibodies in the pres-
ence of 50 µM/L PD 98059 or 10 µM U0126 for 12 h. Explants were 
fixed as described previously (Drake and Fleming, 2000), immunolabeled 
(Baumer et al., 2006), and examined with a fluorescence microscope (Axio-
skop; Carl Zeiss, Inc.) in conjunction with a digital camera (RT KE/SE Spot; 
Diagnostic Instruments, Inc.). For identifying proliferating endothelial cells, 
allantoides were fixed and immunolabeled with anti–PECAM-1 and anti–
phospho-Histone  3  antibodies  as  described  previously  (Baumer  et  al., 
2006). Fluorescence signal was detected using a confocal laser-scan   
microscope (Carl Zeiss, Inc.). Optical sections were collected along the z-axis 
and 3D images were reconstructed using LSM Image Examiner software 
(Video 4). Phospho-Histone 3 positive endothelial cells were counted in 
four volumes (257 × 257 × 24 µm) set randomly per allantois.
Antibody treatment of 1–2-wk-old mice
For treatment of young mice (P7), pups from litters of C57BL/6 mice were 
injected i.p. with 50 µg mAb 109.1 (anti–VE-TP), 1G8.1 (anti-ESAM), pAb 
PTP 1–8 (anti–VE-PTP), or preimmune serum for controls daily for a period 
of 7 or 4 d. Tongues from mouse pups were harvested and fixed in para-
formaldehyde (4% PFA for 3 h); lungs from the same mice were removed 
and rapidly frozen, and tyrosine phosphorylation of Tie-2 was analyzed as 
described previously (Thurston et al., 2005). Longitudinal vibratome sec-
tions (100 µm) of tongues and trachea whole mounts were fixed for an-
other 30 min, permeabilized with 0.5% Triton X-100, and stained with 
mAbs against PECAM-1 and pAbs against phospho-Histone 3, followed by 
detection with Alexa 488– and Alexa 568–coupled secondary antibodies 
and mounted in mowiol (Sigma-Aldrich). Confocal fluorescence images 
were collected using a confocal laser-scan microscope (Carl Zeiss, Inc.). 
Measurements of vessel diameter were performed on three tongues per 
group on four representative regions per tongue. Counting of phospho- 
Histone 3 positive endothelial cells was performed in three tongues per 
group on nine representative regions per tongue.
Live imaging of allantois explants
For live imaging, allantois explants were dissected from E8.0 to E8.5 VE-
cadherin-EGFP expressing embryos, cultured on 0.5% gelatin-coated   
µ-slides (Ibidi) in a live imaging chamber (Ibidi), which guaranteed 85% 
humidity, 5% CO2, and 37°C. After cultivation for 6–12 h, the EGFP fluor-
escence signal was detected using a confocal laser-scan microscope (Carl 
Zeiss, Inc.). Optical sections of the cultured explants were collected along 
the z-axis and collapsed into a single focal plane for each indicated time 
point. After stopping confocal analysis, allantoides were fixed and immuno-
labeled with anti–PECAM-1 and phospho-Histone 3 antibodies as described 
previously (Baumer et al., 2006).
domains  1–8  of  VE-PTP,  pAb  D17  against  the  extracellular  membrane 
proximal fibronectin type III-like domain of VE-PTP, mAb 3G1 against Tie-2 
(Koblizek et al., 1997), mAb against human Tie-2 (Millipore), pAb against 
Tie-1 (Santa Cruz Biotechnology, Inc.), pAb against phospho-Tie-2-Tyr992, 
pAb  against  phospho-Erk1/2-Thr202/Tyr204  pAb  and  mAb  against 
Erk1/2, pAb against phospho-Akt-Ser473, pAb against Akt (Cell Signal-
ing Technology), mAb 11D4.1 and pAb C5 against murine VE-cadherin 
(Gotsch et al., 1997), pAb against human VE-cadherin (Santa Cruz Bio-
technology, Inc.), mAb 1G8 against mouse ESAM (Nasdala et al., 2002), 
pAb against human ESAM (Nottebaum et al., 2008), mAb against PECAM-1 
1G5.1 and 5D2.6 (Wegmann et al., 2006), mAb against plakoglobin   
(BD Biosciences), mAb 4G10 against phosphotyrosine (Millipore), and 
mAb and pAb against phospho-Histone H3-Ser10 (Millipore). Secondary 
antibodies were purchased from Dianova; Alexa 488–, Alexa 633–, and 
Alexa 568–coupled antibodies from Invitrogen; and DyLight680 and   
DyLight800-coupled antibodies from Thermo Fisher Scientific.
Cell culture
The following cells were propagated as described: bEnd.3 and bEnd.5 
(Reiss et al., 1998), Tie2
+/+ and Tie2
/ mouse endothelioma cells (Jones 
et al., 2003), and HUVEC (Baumeister et al., 2005). Polyoma middle T im-
mortalization of embryonic endothelial cells was performed as described 
previously (Reiss and Kiefer, 2004), starting from E9.5 mouse embryos. 
For stimulation with angiopoietins and antibody treatment, bEnd.5 cells 
were grown to confluence in DMEM, 10% FCS, starved with MCDB 131 
medium (Invitrogen) containing 1% BSA overnight, and stimulated with 
200 ng/ml recombinant COMP-angiopoietin-1 (COMP-Ang1) or 600 ng/ml 
Ang1 and Ang2, respectively, in MCDB 131 medium (with 1% BSA) for   
indicated time periods. Cells were treated with 50 µg/ml mAb 109.1 (anti-
VE-TP), 1G8.1 (anti-ESAM), pAb PTP 1–8 (anti-VE-PTP), or preimmune serum 
in starvation medium for 30–90 min. HUVECs were grown to confluence 
in Medium 199 (Invitrogen), 20% FCS, starved with Medium 199 contain-
ing 2% FCS for 6 h and stimulated with angiopoietins as described above 
for bEnd.5 cells.
Constructs and adenoviral transfection
Flag VE-PTP (lacking the first 16 FNIII-like repeats, but containing the extra-
cellular  most  membrane-proximal  17th  domain)  and  Flag  VE-PTP  C/S 
(Fachinger et al., 1999) with a phosphatase-dead mutant (cysteine in the 
active center replaced by seine) were cloned into pENTR 2B (Invitrogen). 
Using the LR Recombination Reaction (Gateway Technology; Invitrogen), 
the pAd-DEST vector was created and used for lipofection of 293A cells. 
The viral lysate was prepared by lysis of the transfected 293A cells.   
HUVECs were transduced with adFlag-VE-PTP or adFlag-VE-PTPC/S for 18 h, 
washed, and starved for 4 h in Medium199, 2% FCS. Subsequently, cells 
were treated with antibodies against the 17th extracellular domain of   
VE-PTP for indicated time periods.
Detection of VE-PTP endocytosis by immunofluorescence staining
For  detection  of  endocytosed  VE-PTP,  bEnd.3  endothelioma  cells  were 
seeded on fibronectin-coated glass chamber slides and grown to conflu-
ence, starved with MCDB 131 medium containing 1% BSA overnight, and 
treated with 50 µg/ml pAb PTP 1–8 (anti-VE-PTP), mAb 109.1 (anti-VE-PTP), 
or control antibodies in starvation medium for indicated time periods. Sub-
sequently,  cells  were  washed  extensively,  fixed  with  paraformaldehyde, 
permeabilized, and blocked with 3% BSA/PBS. Endocytosed antibodies 
were detected with Alexa 568–coupled secondary antibodies. For controls 
cells  were  stained  with  secondary  antibodies  without  permeabilization. 
Cells were immunostained with anti–Tie-2, anti–VE-cadherin, anti-ESAM, 
and anti-EEA1 antibodies for 30 min at room temperature. Subsequently, 
primary antibodies were detected with Alexa 488–, Alexa 568– and Alexa 
633–coupled antibodies for 30 min at room temperature. Cell nuclei were 
counterstained with 10 µg/ml Hoechst in 3% BSA/PBS for 2 min and exam-
ined with a fluorescence microscope (Axioskop; Carl Zeiss, Inc.) in conjunc-
tion with a digital camera (RT KE/SE Spot; Diagnostic Instruments, Inc.) or 
using a confocal laser-scan microscope (Carl Zeiss, Inc.).
Immunoprecipitation and immunoblotting
For coimmunoprecipitations (coIPs), cells were lysed in lysis buffer (20 mM 
imidazole, pH 6.8, 100 mM NaCl, 2 mM CaCl2, 1% Triton X-100, 0.04% 
NaN3, and 1x Complete EDTA-free protease inhibitor cocktail [Roche]). 
For  detection  of  phosphotyrosine  after  immunoprecipitation,  cells  were 
lysed in lysis buffer containing 20 mM Tris-HCl, pH 7.4, 150 mM NaCl,   
2 mM CaCl2, 1 mM Na3VO4, 1% Triton X-100, 0.04% NaN3, and 1x Com-
plete EDTA-free. At no time were intact cells exposed to vanadate or per-
oxyvanadate. Lysates were centrifuged at 4°C for 30 min at 20,000 g, JCB • VOLUME 185 • NUMBER 4 • 2009   670
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Microscopy
All images were acquired using a fluorescence microscope (Axioskop; Carl 
Zeiss, Inc.) with 10×/NA 0.5, 20×/NA 0.75, 40×/NA 0.75, or 100×/
NA 1.3 objectives (Carl Zeiss, Inc.) in conjunction with a digital camera (RT 
KE/SE Spot; Diagnostic Instruments, Inc.). Alternatively, a confocal laser-
scan microscope (510 META; Carl Zeiss, Inc.) was used with 20×/NA 0.8, 
40×/NA 1.2, or 63×/NA 1.4 objectives (Carl Zeiss, Inc.).
Statistical analysis
The endothelial cord diameter measurements in allantois explants were 
made by drawing a straight line from edge to edge of the vessel (diameter) 
at a point in the vessel located mid-distance between adjacent branches. 
The detailed method is illustrated by a drawing in LaRue et al. (2003). 
Western blots were analyzed by measurements of pixel intensity using 
Multi Gauche software (Fujifilm). P-values were calculated by using two-
way Student’s t or Mann-Whitney U tests. Error bars indicate standard de-
viation of the mean
Online supplemental material
Figure S1 shows that polyclonal and monoclonal antibodies against VE-PTP 
trigger vessel enlargement in allantois explants and do not affect junctional 
proteins. Figure S2 demonstrates that endocytosed VE-PTP colocalizes first 
with early endosomes and is subsequently degraded, whereas junctional 
structures stay intact. Figure S3 shows that endogenously expressed Tie-2 
and VE-PTP associate in endothelial cells. Figure S4 shows allantois ex-
plants treated with anti–VE-PTP antibodies in the presence of the Erk1/2 
inhibitor U0126. Figure S5 demonstrates that Tie-2 is no longer cell surface 
distributed as shown in Fig. 3 A, but located at cell–cell contacts upon 
stimulation with COMP-Ang1. The same monoclonal antibody against   
Tie-2 was used as in Fig. 3 A. Videos 1–3 show allantois explants express-
ing VE-cadherin-GFP imaged for 10–14 h in the presence of polyclonal 
antibodies  against  VE-PTP  (Video  2),  preimmune  antibodies  (Video  1), 
or 600 ng/ml COMP-Ang1 in an Ibidi live-imaging chamber (Video 3). 
Video 4 shows an animation of a 3D reconstruction of an allantois cut-
out. Allantois was treated with control antibodies and subsequently stained 
for PECAM-1 and phospho-Histone 3. Videos 5 and 6 show that anti-
bodies against VE-PTP trigger endocytosis of VE-PTP in endothelial cells 
of allantois explant cultures (Video 5) in comparison to preimmune serum 
(Video 6). Video 7 demonstrates that VE-PTP is localized to the cell surface 
and cell–cell contacts in endothelial cells of untreated allantois explant 
cultures.  Online  supplemental  material  is  available  at  http://www.jcb 
.org/cgi/content/full/jcb.200811159/DC1.
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